Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 23;10(6):e0125024.
doi: 10.1371/journal.pone.0125024. eCollection 2015.

Gastrointestinal Disorder Associated with Olmesartan Mimics Autoimmune Enteropathy

Affiliations

Gastrointestinal Disorder Associated with Olmesartan Mimics Autoimmune Enteropathy

Sophie Scialom et al. PLoS One. .

Abstract

Background and objectives: Anti-hypertensive treatment with the angiotensin II receptor antagonist olmesartan is a rare cause of severe Sprue-like enteropathy. To substantiate the hypothesis that olmesartan interferes with gut immune homeostasis, clinical, histopathological and immune features were compared in olmesartan-induced-enteropathy (OIE) and in autoimmune enteropathy (AIE).

Methods: Medical files of seven patients with OIE and 4 patients with AIE enrolled during the same period were retrospectively reviewed. Intestinal biopsies were collected for central histopathological review, T cell Receptor clonality and flow cytometric analysis of isolated intestinal lymphocytes.

Results: Among seven olmesartan-treated patients who developed villous atrophy refractory to a gluten free diet, three had extra-intestinal autoimmune diseases, two had antibodies reacting with the 75 kilodalton antigen characteristic of AIE and one had serum anti-goblet cell antibodies. Small intestinal lesions and signs of intestinal lymphocyte activation were thus reminiscent of the four cases of AIE diagnosed during the same period. Before olmesartan discontinuation, remission was induced in all patients (7/7) by immunosuppressive drugs. After interruption of both olmesartan and immunosuppressive drugs in six patients, remission was maintained in 4 but anti-TNF-α therapy was needed in two.

Conclusion: This case-series shows that olmesartan can induce intestinal damage mimicking AIE. OIE usually resolved after olmesartan interruption but immunosuppressive drugs may be necessary to achieve remission. Our data sustain the hypothesis that olmesartan interferes with intestinal immuno regulation in predisposed individuals.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. H&E staining of the duodenal biopsies of one patient treated with Olmesartan (patient 2) (A, B) and of one patient with AIE (patient 7) (C, D) showing subtotal villous atrophy (A, C: original magnification x 100) with glandular apoptosis (B, D: original magnification x200).

References

    1. Systematic review: Sprue-like enteropathy associated with olmesartan.Ianiro G, Bibbò S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Aliment PharmacolTher. 2014. July;40(1):16–23. 10.1111/apt.12780 - DOI - PubMed
    1. Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, et al. Severe spruelikeenteropathy associated with olmesartan. Mayo Clin Proc 2012; 87:732–8 10.1016/j.mayocp.2012.06.003 - DOI - PMC - PubMed
    1. DeGaetani M, Tennyson CA, Lebwohl B, Lewis SK, Abu Daya H, Arguelles-Grande C,et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma.Am J Gastroenterol. 2013. May;108(5):647–53 10.1038/ajg.2013.45 - DOI - PubMed
    1. Olmesartan-associated enteropathy: results of a national survey. Marthey L, Cadiot G, Seksik P, Pouderoux P, Lacroute J, Skinazi F, et al. Aliment PharmacolTher. 2014. November;40(9):1103–9. 10.1111/apt.12937 - DOI - PubMed
    1. Malamut G, Verkarre V, Callens C, Colussi O, Rahmi G, MacIntyre E, et al. Enteropathy Associated T cell Lymphoma complicating an Autoimmune Enteropathy. Gastroenterology 2012;142:726–729 10.1053/j.gastro.2011.12.040 - DOI - PubMed

Supplementary concepts

LinkOut - more resources